Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal. / Thompson, Alan J.; Carroll, William; Ciccarelli, Olga; Comi, Giancarlo; Cross, Anne; Donnelly, Alexis; Feinstein, Anthony; Fox, Robert J.; Helme, Anne; Hohlfeld, Reinhard; Hyde, Robert; Kanellis, Pamela; Landsman, Douglas; Lubetzki, Catherine; Marrie, Ruth Ann; Morahan, Julia; Montalban, Xavier; Musch, Bruno; Rawlings, Sarah; Salvetti, Marco; Sellebjerg, Finn; Sincock, Caroline; Smith, Kathryn E.; Strum, Jon; Zaratin, Paola; Coetzee, Timothy.

I: Multiple Sclerosis Journal, Bind 28, Nr. 1, 01.2022, s. 16-28.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Thompson, AJ, Carroll, W, Ciccarelli, O, Comi, G, Cross, A, Donnelly, A, Feinstein, A, Fox, RJ, Helme, A, Hohlfeld, R, Hyde, R, Kanellis, P, Landsman, D, Lubetzki, C, Marrie, RA, Morahan, J, Montalban, X, Musch, B, Rawlings, S, Salvetti, M, Sellebjerg, F, Sincock, C, Smith, KE, Strum, J, Zaratin, P & Coetzee, T 2022, 'Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal', Multiple Sclerosis Journal, bind 28, nr. 1, s. 16-28. https://doi.org/10.1177/13524585211059766

APA

Thompson, A. J., Carroll, W., Ciccarelli, O., Comi, G., Cross, A., Donnelly, A., Feinstein, A., Fox, R. J., Helme, A., Hohlfeld, R., Hyde, R., Kanellis, P., Landsman, D., Lubetzki, C., Marrie, R. A., Morahan, J., Montalban, X., Musch, B., Rawlings, S., ... Coetzee, T. (2022). Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal. Multiple Sclerosis Journal, 28(1), 16-28. https://doi.org/10.1177/13524585211059766

Vancouver

Thompson AJ, Carroll W, Ciccarelli O, Comi G, Cross A, Donnelly A o.a. Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal. Multiple Sclerosis Journal. 2022 jan.;28(1):16-28. https://doi.org/10.1177/13524585211059766

Author

Thompson, Alan J. ; Carroll, William ; Ciccarelli, Olga ; Comi, Giancarlo ; Cross, Anne ; Donnelly, Alexis ; Feinstein, Anthony ; Fox, Robert J. ; Helme, Anne ; Hohlfeld, Reinhard ; Hyde, Robert ; Kanellis, Pamela ; Landsman, Douglas ; Lubetzki, Catherine ; Marrie, Ruth Ann ; Morahan, Julia ; Montalban, Xavier ; Musch, Bruno ; Rawlings, Sarah ; Salvetti, Marco ; Sellebjerg, Finn ; Sincock, Caroline ; Smith, Kathryn E. ; Strum, Jon ; Zaratin, Paola ; Coetzee, Timothy. / Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal. I: Multiple Sclerosis Journal. 2022 ; Bind 28, Nr. 1. s. 16-28.

Bibtex

@article{dbe80211d2a941d48a1e558115eec329,
title = "Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal",
abstract = "Background: Progressive forms of multiple sclerosis (MS) affect more than 1 million individuals globally. Recent approvals of ocrelizumab for primary progressive MS and siponimod for active secondary progressive MS have opened the therapeutic door, though results from early trials of neuroprotective agents have been mixed. The recent introduction of the term 'active' secondary progressive MS into the therapeutic lexicon has introduced potential confusion to disease description and thereby clinical management. Objective: This paper reviews recent progress, highlights continued knowledge and proposes, on behalf of the International Progressive MS Alliance, a global research strategy for progressive MS. Methods: Literature searches of PubMed between 2015 and May, 2021 were conducted using the search terms {"}progressive multiple sclerosis{"}, {"}primary progressive multiple sclerosis{"}, {"}secondary progressive MS{"}. Proposed strategies were developed through a series of in-person and virtual meetings of the International Progressive MS Alliance Scientific Steering Committee. Results: Sustaining and accelerating progress will require greater understanding of underlying mechanisms, identification of potential therapeutic targets, biomarker discovery and validation, and conduct of clinical trials with improved trial design. Encouraging developments in symptomatic and rehabilitative interventions are starting to address ongoing challenges experienced by people with progressive MS. Conclusion: We need to manage these challenges and realise the opportunities in the context of a global research strategy, which will improve quality of life for people with progressive MS.",
keywords = "Multiple sclerosis, progressive, progression, progressive multiple sclerosis, NEUROFILAMENT LIGHT LEVELS, MULTIPLE-SCLEROSIS, DOUBLE-BLIND, NATURAL-HISTORY, MRI MEASURES, DISABILITY, PLACEBO, MATTER, EFFICACY, OUTCOMES",
author = "Thompson, {Alan J.} and William Carroll and Olga Ciccarelli and Giancarlo Comi and Anne Cross and Alexis Donnelly and Anthony Feinstein and Fox, {Robert J.} and Anne Helme and Reinhard Hohlfeld and Robert Hyde and Pamela Kanellis and Douglas Landsman and Catherine Lubetzki and Marrie, {Ruth Ann} and Julia Morahan and Xavier Montalban and Bruno Musch and Sarah Rawlings and Marco Salvetti and Finn Sellebjerg and Caroline Sincock and Smith, {Kathryn E.} and Jon Strum and Paola Zaratin and Timothy Coetzee",
year = "2022",
month = jan,
doi = "10.1177/13524585211059766",
language = "English",
volume = "28",
pages = "16--28",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications",
number = "1",

}

RIS

TY - JOUR

T1 - Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal

AU - Thompson, Alan J.

AU - Carroll, William

AU - Ciccarelli, Olga

AU - Comi, Giancarlo

AU - Cross, Anne

AU - Donnelly, Alexis

AU - Feinstein, Anthony

AU - Fox, Robert J.

AU - Helme, Anne

AU - Hohlfeld, Reinhard

AU - Hyde, Robert

AU - Kanellis, Pamela

AU - Landsman, Douglas

AU - Lubetzki, Catherine

AU - Marrie, Ruth Ann

AU - Morahan, Julia

AU - Montalban, Xavier

AU - Musch, Bruno

AU - Rawlings, Sarah

AU - Salvetti, Marco

AU - Sellebjerg, Finn

AU - Sincock, Caroline

AU - Smith, Kathryn E.

AU - Strum, Jon

AU - Zaratin, Paola

AU - Coetzee, Timothy

PY - 2022/1

Y1 - 2022/1

N2 - Background: Progressive forms of multiple sclerosis (MS) affect more than 1 million individuals globally. Recent approvals of ocrelizumab for primary progressive MS and siponimod for active secondary progressive MS have opened the therapeutic door, though results from early trials of neuroprotective agents have been mixed. The recent introduction of the term 'active' secondary progressive MS into the therapeutic lexicon has introduced potential confusion to disease description and thereby clinical management. Objective: This paper reviews recent progress, highlights continued knowledge and proposes, on behalf of the International Progressive MS Alliance, a global research strategy for progressive MS. Methods: Literature searches of PubMed between 2015 and May, 2021 were conducted using the search terms "progressive multiple sclerosis", "primary progressive multiple sclerosis", "secondary progressive MS". Proposed strategies were developed through a series of in-person and virtual meetings of the International Progressive MS Alliance Scientific Steering Committee. Results: Sustaining and accelerating progress will require greater understanding of underlying mechanisms, identification of potential therapeutic targets, biomarker discovery and validation, and conduct of clinical trials with improved trial design. Encouraging developments in symptomatic and rehabilitative interventions are starting to address ongoing challenges experienced by people with progressive MS. Conclusion: We need to manage these challenges and realise the opportunities in the context of a global research strategy, which will improve quality of life for people with progressive MS.

AB - Background: Progressive forms of multiple sclerosis (MS) affect more than 1 million individuals globally. Recent approvals of ocrelizumab for primary progressive MS and siponimod for active secondary progressive MS have opened the therapeutic door, though results from early trials of neuroprotective agents have been mixed. The recent introduction of the term 'active' secondary progressive MS into the therapeutic lexicon has introduced potential confusion to disease description and thereby clinical management. Objective: This paper reviews recent progress, highlights continued knowledge and proposes, on behalf of the International Progressive MS Alliance, a global research strategy for progressive MS. Methods: Literature searches of PubMed between 2015 and May, 2021 were conducted using the search terms "progressive multiple sclerosis", "primary progressive multiple sclerosis", "secondary progressive MS". Proposed strategies were developed through a series of in-person and virtual meetings of the International Progressive MS Alliance Scientific Steering Committee. Results: Sustaining and accelerating progress will require greater understanding of underlying mechanisms, identification of potential therapeutic targets, biomarker discovery and validation, and conduct of clinical trials with improved trial design. Encouraging developments in symptomatic and rehabilitative interventions are starting to address ongoing challenges experienced by people with progressive MS. Conclusion: We need to manage these challenges and realise the opportunities in the context of a global research strategy, which will improve quality of life for people with progressive MS.

KW - Multiple sclerosis

KW - progressive

KW - progression

KW - progressive multiple sclerosis

KW - NEUROFILAMENT LIGHT LEVELS

KW - MULTIPLE-SCLEROSIS

KW - DOUBLE-BLIND

KW - NATURAL-HISTORY

KW - MRI MEASURES

KW - DISABILITY

KW - PLACEBO

KW - MATTER

KW - EFFICACY

KW - OUTCOMES

U2 - 10.1177/13524585211059766

DO - 10.1177/13524585211059766

M3 - Journal article

C2 - 34850641

VL - 28

SP - 16

EP - 28

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

SN - 1352-4585

IS - 1

ER -

ID: 314714090